PPARα as a therapeutic target in inflammation-associated diseases (Q38038289)

27 August 2017

PPARα as a therapeutic target in inflammation-associated diseases (English)

1 reference

27 August 2017

0 references

Philippe Gervois

1

1 reference

PubMed ID

22925108

27 August 2017

Roxane M Mansouri

series ordinal

2

1 reference

PubMed ID

22925108

27 August 2017

language of work or name

English

0 references

publication date

27 August 2012

1 reference

Expert Opinion on Therapeutic Targets

27 August 2017

1 reference

27 August 2017

16

1 reference

27 August 2017

1113-1125

1 reference

27 August 2017

11

1 reference

Molecular mechanisms of action of steroid/thyroid receptor superfamily members

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

The nuclear receptor superfamily: the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARs and lipid ligands in inflammation and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Identification of a physiologically relevant endogenous ligand for PPARalpha in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Regulation of inflammatory and lipid metabolism genes by eicosapentaenoic acid-rich oil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Modulation of immune and inflammatory responses by dietary lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

The PPARalpha-leukotriene B4 pathway to inflammation control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Smad proteins suppress CCAAT/enhancer-binding protein (C/EBP) beta- and STAT3-mediated transcriptional activation of the haptoglobin promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Synergistic activity of STAT3 and c-Jun at a specific array of DNA elements in the alpha 2-macroglobulin promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Peroxisome proliferator-activated receptor-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARs in atherosclerosis: the clot thickens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Potential role of nuclear factor κB in diabetic cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

The NF-κB subunit c-Rel stimulates cardiac hypertrophy and fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

PPARgamma as a new therapeutic target in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Hepatic response to sepsis: interaction between coagulation and inflammatory processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

Role of novel markers of inflammation in patients with stable coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.715633

10.1517/14728222.2012.715633

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22925108